96,685 Shares in Exact Sciences Corporation $EXAS Purchased by Capricorn Fund Managers Ltd

Capricorn Fund Managers Ltd acquired a new stake in shares of Exact Sciences Corporation (NASDAQ:EXAS) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 96,685 shares of the medical research company’s stock, valued at approximately $9,819,000. Exact Sciences makes up about 2.4% of Capricorn Fund Managers Ltd’s portfolio, making the stock its 9th biggest position. Capricorn Fund Managers Ltd owned approximately 0.05% of Exact Sciences at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in EXAS. Walkner Condon Financial Advisors LLC lifted its stake in shares of Exact Sciences by 16.5% in the 4th quarter. Walkner Condon Financial Advisors LLC now owns 11,217 shares of the medical research company’s stock valued at $1,139,000 after purchasing an additional 1,588 shares during the period. Sowell Financial Services LLC bought a new position in Exact Sciences in the fourth quarter worth $301,000. Park Capital Management LLC WI bought a new position in Exact Sciences in the fourth quarter worth $234,000. Signaturefd LLC lifted its position in Exact Sciences by 5.5% during the fourth quarter. Signaturefd LLC now owns 2,346 shares of the medical research company’s stock valued at $238,000 after buying an additional 123 shares during the period. Finally, eCIO Inc. purchased a new position in Exact Sciences during the fourth quarter valued at $340,000. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on EXAS shares. BTIG Research reaffirmed a “neutral” rating on shares of Exact Sciences in a research report on Tuesday, March 24th. Mizuho reissued a “neutral” rating and set a $105.00 price objective (up from $85.00) on shares of Exact Sciences in a research note on Tuesday, January 20th. Zacks Research cut shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Evercore set a $105.00 target price on shares of Exact Sciences and gave the company an “in-line” rating in a research note on Monday, January 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Exact Sciences in a report on Thursday, January 22nd. Twenty-one analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Exact Sciences has an average rating of “Reduce” and a consensus price target of $92.13.

Exact Sciences Price Performance

EXAS opened at $104.91 on Monday. The firm has a market cap of $20.03 billion, a PE ratio of -95.37, a P/E/G ratio of 2.02 and a beta of 1.41. The stock has a 50-day moving average price of $103.57 and a 200-day moving average price of $89.70. Exact Sciences Corporation has a 1 year low of $38.81 and a 1 year high of $104.98. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.43 and a quick ratio of 2.17.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.29). The firm had revenue of $878.38 million for the quarter, compared to analysts’ expectations of $860.59 million. Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. The business’s revenue for the quarter was up 23.1% compared to the same quarter last year. During the same period last year, the company posted ($0.06) earnings per share. Sell-side analysts predict that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

About Exact Sciences

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.